SinoMab BioScience Profit margin
What is the Profit margin of SinoMab BioScience?
The Profit margin of SinoMab BioScience Limited is -5,537.81%
What is the definition of Profit margin?
Profit margin is a measure of profitability and is calculated by finding the net profit as a percentage of the revenue.
lfy (last fiscal year)
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Profit margin of companies in the Health Care sector on HKSE compared to SinoMab BioScience
What does SinoMab BioScience do?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Companies with profit margin similar to SinoMab BioScience
- Touchpoint has Profit margin of -5,708.79%
- Real Luck has Profit margin of -5,700.00%
- Malachite Resources has Profit margin of -5,693.33%
- Ardea Resources has Profit margin of -5,653.33%
- King Island Scheelite has Profit margin of -5,594.26%
- Vango Mining has Profit margin of -5,538.46%
- SinoMab BioScience has Profit margin of -5,537.81%
- RAPT Therapeutics has Profit margin of -5,490.37%
- Graphene Manufacturing has Profit margin of -5,482.35%
- Energous has Profit margin of -5,474.06%
- Tanga Resources has Profit margin of -5,428.57%
- Zonetail has Profit margin of -5,421.05%
- Kopore Metals has Profit margin of -5,391.30%